Moteur de recherche d’entreprises européennes
Financement de l’UE (4 076 578 €) : Sécrétion, autophagie et leur rôle dans la neurodégénérescence Hor23/09/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Sécrétion, autophagie et leur rôle dans la neurodégénérescence
Neurodegenerative disorders are among the leading causes of mortality and will become more relevant in our continuously aging societies. Most neurodegenerative disorders exhibit alterations in proteostasis, i.e. an imbalance between protein production, sorting and degradation. The secretory and the autophagic pathways are two major regulators of cellular proteostasis and their crosstalk is likely to be relevant for neurodegeneration. Thus, there is a need to train a new generation of early stage researchers that will exploit and translate the fundamental biology principles of autophagy, secretion and their crosstalk in human diseases. Our ETN will explore the links between Secretion, Autophagy and their role in NeuroDegeneration (SAND) and will consolidate the position of Europe as a leader in this field by: (i) providing a framework for training and supervision of students to provide them with a repertoire of transferrable and scientific skills that will equip them for careers in academia and industry. (ii) bringing together leading experts in the fields of autophagy, secretion and neurodegeneration from academia and industry into a consortium that involves 22 participants from 12 countries (12 academic beneficiaries from 13 institutions, 3 industry beneficiaries, 4 non-academic partners and 3 academic partner institutions) (iii) using a unifying strategy such as a common stock of cell lines for screening and a common electronic custom-made database tailored to the needs of our consortium (iv) combining complementary expertise such as systems biology, chemical biology, model organisms (zebrafish, drosophila and mouse models), cellular models (neuronal cell lines, primary neurons and patient-derived iPSC neurons) and techniques (e.g. EM, intravital imaging, proteomics, microfluidics) (v) exploiting the translational potential because the network contains three clinically active neurologists, non-academic partners interested in development of drugs and diagnost
| 4Dcell | 213 735 € |
| Cell Stress Discoveries Ltd. | 274 684 € |
| Darwin Microfluidics | 0,00 € |
| ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE | 281 277 € |
| Institut National de la Sante et de la Recherche Medicale | 0,00 € |
| Karolinska Institutet | 281 983 € |
| KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW | 36 892 € |
| LEIBNIZ-INSTITUT FUR ALTERNSFORSCHUNG - FRITZ-LIPMANN-INSTITUT EV (FLI) LEIBNIZ INSTITUTE ON AGING - FRITZ LIPMANN INSTITUTE e. V. (FLI) | 252 788 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 505 577 € |
| Medizinische Universitat Innsbruck | 176 138 € |
| PRE Diagnostics AS | 292 342 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 303 173 € |
| The University of Edinburgh | 303 173 € |
| Universita Degli Studi Di Milano | 261 500 € |
| UNIVERSITAET BERN | 274 799 € |
| UNIVERSITEIT UTRECHT | 228 728 € |
| Universitetet I Oslo | 389 790 € |
https://cordis.europa.eu/project/id/860035
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "4Dcell - Financement de l’UE (4 076 578 €) : Sécrétion, autophagie et leur rôle dans la neurodégénérescence"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
